BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9815718)

  • 1. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.
    Chen CC; Meadows B; Regis J; Kalafsky G; Fojo T; Carrasquillo JA; Bates SE
    Clin Cancer Res; 1997 Apr; 3(4):545-52. PubMed ID: 9815718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
    Agrawal M; Abraham J; Balis FM; Edgerly M; Stein WD; Bates S; Fojo T; Chen CC
    Clin Cancer Res; 2003 Feb; 9(2):650-6. PubMed ID: 12576431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
    Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
    Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours.
    Bakker M; van der Graaf WT; Piers DA; Franssen EJ; Groen HJ; Smit EF; Kool W; Hollema H; Müller EA; De Vries EG
    Anticancer Res; 1999; 19(3B):2349-53. PubMed ID: 10472354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
    Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
    J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of multidrug resistance: lessons from clinical oncology.
    Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
    Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
    Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging.
    Wang JH; Scollard DA; Teng S; Reilly RM; Piquette-Miller M
    J Nucl Med; 2005 Sep; 46(9):1537-45. PubMed ID: 16157538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.
    Gomes CM; Abrunhosa AJ; Pauwels EK; Botelho MF
    Cancer Biother Radiopharm; 2009 Apr; 24(2):215-27. PubMed ID: 19409044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of P-glycoprotein transport and inhibition in vivo.
    Barbarics E; Kronauge JF; Cohen D; Davison A; Jones AG; Croop JM
    Cancer Res; 1998 Jan; 58(2):276-82. PubMed ID: 9443405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.
    Peck RA; Hewett J; Harding MW; Wang YM; Chaturvedi PR; Bhatnagar A; Ziessman H; Atkins F; Hawkins MJ
    J Clin Oncol; 2001 Jun; 19(12):3130-41. PubMed ID: 11408511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
    Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
    J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein.
    Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B
    Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
    Kostakoglu L; Elahi N; Kïratlï P; Ruacan S; Sayek I; Baltalï E; Sungur A; Hayran M; Bekdik CF
    J Nucl Med; 1997 Jul; 38(7):1003-8. PubMed ID: 9225779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
    Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
    Oncologist; 2012; 17(4):512. PubMed ID: 22416063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG.
    Krasznai ZT; Tóth A; Mikecz P; Fodor Z; Szabó G; Galuska L; Hernádi Z; Goda K
    Eur J Pharm Sci; 2010 Dec; 41(5):665-9. PubMed ID: 20869436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-small cell lung cancer functional imaging: increased hexakis-2-methoxy-isobutyl-isonitrile tumor clearance correlates with resistance to cytotoxic treatment.
    Koukourakis MI; Koukouraki S; Giatromanolaki A; Skarlatos J; Georgoulias V; Karkavitsas N
    Clin Cancer Res; 1997 May; 3(5):749-54. PubMed ID: 9815745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
    Del Vecchio S; Ciarmiello A; Pace L; Potena MI; Carriero MV; Mainolfi C; Thomas R; D'Aiuto G; Tsuruo T; Salvatore M
    J Nucl Med; 1997 Sep; 38(9):1348-51. PubMed ID: 9293785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
    Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
    J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.